These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34758724)

  • 1. The low-complexity domains of the KMT2D protein regulate histone monomethylation transcription to facilitate pancreatic cancer progression.
    Li W; Wu L; Jia H; Lin Z; Zhong R; Li Y; Jiang C; Liu S; Zhou X; Zhang E
    Cell Mol Biol Lett; 2021 Nov; 26(1):45. PubMed ID: 34758724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
    Lv S; Ji L; Chen B; Liu S; Lei C; Liu X; Qi X; Wang Y; Lai-Han Leung E; Wang H; Zhang L; Yu X; Liu Z; Wei Q; Lu L
    Oncogene; 2018 Mar; 37(10):1354-1368. PubMed ID: 29269867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
    Guo C; Chen LH; Huang Y; Chang CC; Wang P; Pirozzi CJ; Qin X; Bao X; Greer PK; McLendon RE; Yan H; Keir ST; Bigner DD; He Y
    Oncotarget; 2013 Nov; 4(11):2144-53. PubMed ID: 24240169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C
    Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KMT2D inhibits the growth and metastasis of bladder Cancer cells by maintaining the tumor suppressor genes.
    Sun P; Wu T; Sun X; Cui Z; Zhang H; Xia Q; Zhang D
    Biomed Pharmacother; 2019 Jul; 115():108924. PubMed ID: 31100540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone H3 lysine 4 methyltransferase KMT2D.
    Froimchuk E; Jang Y; Ge K
    Gene; 2017 Sep; 627():337-342. PubMed ID: 28669924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
    Alam H; Tang M; Maitituoheti M; Dhar SS; Kumar M; Han CY; Ambati CR; Amin SB; Gu B; Chen TY; Lin YH; Chen J; Muller FL; Putluri N; Flores ER; DeMayo FJ; Baseler L; Rai K; Lee MG
    Cancer Cell; 2020 Apr; 37(4):599-617.e7. PubMed ID: 32243837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KMT2D regulates p63 target enhancers to coordinate epithelial homeostasis.
    Lin-Shiao E; Lan Y; Coradin M; Anderson A; Donahue G; Simpson CL; Sen P; Saffie R; Busino L; Garcia BA; Berger SL; Capell BC
    Genes Dev; 2018 Jan; 32(2):181-193. PubMed ID: 29440247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EBF2 Links KMT2D-Mediated H3K4me1 to Suppress Pancreatic Cancer Progression via Upregulating KLLN.
    Yao B; Xing M; Meng S; Li S; Zhou J; Zhang M; Yang C; Qu S; Jin Y; Yuan H; Zen K; Ma C
    Adv Sci (Weinh); 2024 Jan; 11(2):e2302037. PubMed ID: 38015024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysine Methyltransferase 2D Regulates Immune Response and Metastasis in Head and Neck Cancer.
    Wu J; Chun C; Lagunas AM; Crowe DL
    Anticancer Res; 2024 Aug; 44(8):3231-3242. PubMed ID: 39060071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
    Lv S; Wen H; Shan X; Li J; Wu Y; Yu X; Huang W; Wei Q
    Epigenetics; 2019 Dec; 14(12):1194-1208. PubMed ID: 31232159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.
    Gao W; Jia Z; Tian Y; Yang P; Sun H; Wang C; Ding Y; Zhang M; Zhang Y; Yang D; Tian Z; Zhou J; Ruan Z; Wu Y; Ni B
    Hepatology; 2020 May; 71(5):1678-1695. PubMed ID: 31544250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer.
    Xiong W; Deng Z; Tang Y; Deng Z; Li M
    Biochem Biophys Res Commun; 2018 Sep; 504(1):129-136. PubMed ID: 30177394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed lineage leukemia 5 (MLL5) protein regulates cell cycle progression and E2F1-responsive gene expression via association with host cell factor-1 (HCF-1).
    Zhou P; Wang Z; Yuan X; Zhou C; Liu L; Wan X; Zhang F; Ding X; Wang C; Xiong S; Wang Z; Yuan J; Li Q; Zhang Y
    J Biol Chem; 2013 Jun; 288(24):17532-43. PubMed ID: 23629655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A non-active-site SET domain surface crucial for the interaction of MLL1 and the RbBP5/Ash2L heterodimer within MLL family core complexes.
    Shinsky SA; Hu M; Vought VE; Ng SB; Bamshad MJ; Shendure J; Cosgrove MS
    J Mol Biol; 2014 Jun; 426(12):2283-99. PubMed ID: 24680668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
    Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
    J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KMT2C and KMT2D aberrations in breast cancer.
    Tinsley E; Bredin P; Toomey S; Hennessy BT; Furney SJ
    Trends Cancer; 2024 Jun; 10(6):519-530. PubMed ID: 38453563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mll3 and Mll4 Facilitate Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4 Monomethylation.
    Dorighi KM; Swigut T; Henriques T; Bhanu NV; Scruggs BS; Nady N; Still CD; Garcia BA; Adelman K; Wysocka J
    Mol Cell; 2017 May; 66(4):568-576.e4. PubMed ID: 28483418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.
    Sun Y; Bell JL; Carter D; Gherardi S; Poulos RC; Milazzo G; Wong JW; Al-Awar R; Tee AE; Liu PY; Liu B; Atmadibrata B; Wong M; Trahair T; Zhao Q; Shohet JM; Haupt Y; Schulte JH; Brown PJ; Arrowsmith CH; Vedadi M; MacKenzie KL; Hüttelmaier S; Perini G; Marshall GM; Braithwaite A; Liu T
    Cancer Res; 2015 Dec; 75(23):5143-54. PubMed ID: 26471359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
    Maitituoheti M; Keung EZ; Tang M; Yan L; Alam H; Han G; Singh AK; Raman AT; Terranova C; Sarkar S; Orouji E; Amin SB; Sharma S; Williams M; Samant NS; Dhamdhere M; Zheng N; Shah T; Shah A; Axelrad JB; Anvar NE; Lin YH; Jiang S; Chang EQ; Ingram DR; Wang WL; Lazar A; Lee MG; Muller F; Wang L; Ying H; Rai K
    Cell Rep; 2020 Oct; 33(3):108293. PubMed ID: 33086062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.